Gland Pharma · GLAND
Gland Pharma's growth is running into the limits of its own plants
Sales rose 21.4% in the first half, yet Gland Pharma held its 15% growth guidance for the year, saying its vial lines are nearly full as it commits more money to new ones.
4 min read Published on
Published by
Inve Content team
Gland Pharma makes injectable medicines, developing its own products for partners to sell and manufacturing other companies' products under contract. In the first half of this financial year its sales rose 21.4% on a year earlier. On 6 November management nonetheless kept its guidance for full-year growth at 15% in constant currency. The limit it described was its factories rather than its customers: the lines that fill liquid vials are already 92% used, and the company expects next year's demand to exceed what they can make.
Much of the headline growth comes from one step taken a year ago. Quarterly sales jumped between the second and third quarters of the last financial year and have edged up only a little in each quarter since, so that sales in the September 2026 quarter were 23.3% above a year earlier. Once the comparison reaches the stepped-up quarters, year-on-year growth slows even if sales simply hold.
Gland's sales stepped up once, a year ago, and have edged higher in each quarter since
₹ cr
Quarterly sales
- ₹1,506 crore Q1 FY26
- ₹1,487 crore Q2 FY26
- ₹1,695 crore Q3 FY26
- ₹1,743 crore Q4 FY26
- ₹1,800 crore Q1 FY27
- ₹1,834 crore Q2 FY27
That arithmetic is why the unchanged guidance asks so little of the second half. Calculated from the reported quarterly sales in rupees, a 15% year needs second-half sales only about 9.4% above the same half a year earlier, a little above last quarter's level, held for two more quarters. The guidance itself is measured in constant currency, so the rupee figure is an approximation.
A 15% year needs only about 9% growth in the second half, well below the first half's pace
%
- First half, actual 21.4%
- Full-year guidance 15%
- Second half, implied 9.41%
The guidance has moved before. In May the company expected growth of 12-13% for the year; in August it raised it to the level it holds now and said a new line for drugs filled in bags could take growth higher if it won approval in the third quarter, as it then expected. That line is still awaiting an inspection by the US Food and Drug Administration, after which the company says it could ease the squeeze on supply.
Management's description of its plants explains the caution. Its rule, the executive chairman said, used to be to order new lines once idle capacity fell to about a fifth, though it had slowed on that during recent ups and downs. Now, in his words, "we are struggling for capacities", and some lines are so busy that planned maintenance shutdowns have been skipped. The company added ₹1,000 crore for three more vial lines at its existing site, which brings the expansion to about ₹3,000 crore, before a new greenfield plant whose cost has not yet been set.
The spending has started, but the new capacity is not yet working. Capital work in progress, the cost of plant being built but not yet in use, rose to ₹450 crore at the end of September from ₹209 crore a year earlier, while fixed assets in service barely changed. The expansion committed so far, before the greenfield plant, is close to the net cash the company reported, about ₹3,200 crore at the end of September, a little below the figure three months earlier.
Plant under construction has nearly tripled since March 2025
₹ cr
Capital work in progress
- ₹151 crore Mar 2025
- ₹209 crore Sep 2025
- ₹342 crore Mar 2026
- ₹450 crore Sep 2026
The payback is some way off. The new vial lines are meant for contracts whose revenue begins from FY30, and management said only some of those contracts are take-or-pay, under which customers pay for agreed volumes whether or not they take them.
In the meantime the cost of growing shows up in the quarter. Operating margin slipped to 26.4% from 27.2% the quarter before, as research spending rose and Cenexi, Gland's European contract manufacturer, made an EBITDA loss, meaning earnings before interest, tax, depreciation and amortisation, during planned annual shutdowns. Management kept its target of about €200 million in Cenexi revenue this year, with an EBITDA margin it put in May at mid to high single digits, although it also said Cenexi's revenue would grow only minimally.
There is a case that the guidance is a floor rather than a ceiling. The guidance strips out currency moves and, as the company said in May, leaves out any revenue from GLP-1 drugs; the quarter also carried a delayed Saudi tender that held back sales in its smaller markets. The next markers are concrete: the FDA inspection of the bag line, and the board approval for greenfield spending that management plans to seek in the coming quarter.
The record: full financial tables
Financials
Income statement, last 8 quarters
| Quarter end | Sales | YoY | Operating profit | Op. margin | Other income | PBT | Net profit |
|---|---|---|---|---|---|---|---|
| Sept 2026 | 1,834 | +23.3% | 484 | 26.4% | 69 | 431 | 291 |
| Jun 2026 | 1,800 | +19.5% | 489 | 27.2% | 61 | 435 | 317 |
| Mar 2026 | 1,743 | +22.3% | 513 | 29.4% | 111 | 506 | 367 |
| Dec 2025 | 1,695 | +22.5% | 435 | 25.7% | 39 | 362 | 261 |
| Sept 2025 | 1,487 | +5.8% | 314 | 21.1% | 84 | 284 | 184 |
| Jun 2025 | 1,506 | +7.4% | 368 | 24.4% | 58 | 313 | 215 |
| Mar 2025 | 1,425 | −7.3% | 348 | 24.4% | 44 | 288 | 187 |
| Dec 2024 | 1,384 | −10.4% | 360 | 26.0% | 58 | 299 | 205 |
Balance sheet
| As of | Equity | Debt | Investments | Fixed assets | CWIP | Total assets |
|---|---|---|---|---|---|---|
| Sept 2026 | 10,685 | 251 | 0.0 | 4,397 | 450 | 12,927 |
| Mar 2026 | 10,357 | 284 | 0.0 | 4,492 | 342 | 12,449 |
| Sept 2025 | 9,562 | 302 | 0.0 | 4,403 | 209 | 11,800 |
| Mar 2025 | 9,150 | 314 | 0.0 | 4,147 | 151 | 11,173 |
Cash flow
| Year end | Operating | Investing | Financing | Free cash flow |
|---|---|---|---|---|
| Mar 2026 | 1,031 | 188 | −417 | 538 |
| Mar 2025 | 915 | 1,718 | −433 | 521 |
| Mar 2024 | 997 | −1,749 | −799 | 599 |
| Mar 2023 | 364 | 1,211 | 15 | 141 |